Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Regelmäßige Leser wissen, dass wir bei Simply Wall St unsere Dividenden sehr schätzen, daher ist es aufregend zu sehen, dass Symrise AG (ETR:SY1) bald ex-dividenden gehen wird. Der ex-Dividenden-Tag tritt in der Regel zwei Tage vor dem Record-Tag ein, an dem Aktionäre auf den Buchungen der Gesellschaft stehen müssen, um eine Dividende zu erhalten. Der ex-Dividenden-Tag ist ein wichtiger Termin, auf den man achten sollte, da jede Kaufentscheidung nach diesem Datum möglicherweise zu einer verspäteten Abrechnung führen kann, die nicht auf dem Record-Tag erscheint. Das bedeutet, dass Investoren, die Symrise-Aktien am 7. Mai kaufen, keine Dividende erhalten werden, die am 11. Mai ausgezahlt wird.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Symrise logo

Key Points

Symrise said Q1 came in “ahead of expectations” with organic sales down -0.4% year‑over‑year; performance was mixed by segment—Taste, Nutrition & Health +1.7% versus Scent & Care -3.4%—and regionally North America, Latin America and Asia grew while EMEA -4.9% weighed on the group. The company is accelerating its ONE SYM transformation, having delivered about EUR 100m of cumulative savings and ~280 bps of margin expansion since 2023, while expanding capacity (new pet‑food site in Querétaro) and taking a stake in Bond Pet Foods to support innovation and sustainable protein exposure. Management plans price increases and surcharges to offset rising freight/logistics and raw‑material costs, and reiterated full‑year 2026 guidance of 2%–4% organic growth, adjusted EBITDA margin 21.5%–22.5%, and midterm targets of 5%–7% organic growth (2025–2028). Interested in Symrise AG? Here are five stocks we like better.

Symrise (ETR:SY1) reported a first-quarter 2026 performance that management said came in “ahead of expectations,” as the company navigated a weak macroeconomic backdrop, difficult year-ago comparisons, and emerging input-cost uncertainty tied largely to freight and logistics.

On the company’s Q1 2026 trading statement call, CEO Jean-Yves Parisot said the group posted an organic sales decline of 0.4% year over year, compared with what the company had expected coming into the year. He attributed resilience to portfolio balance and execution, while emphasizing that Symrise is accelerating its ONE SYM transformation to fund reinvestment in growth.

Q1 sales: modest organic decline with mixed segment performance

→ Pipelines and Automation: 2 Energy Plays Built for Any Oil Price

Parisot said Q1 sales were “stronger than anticipated,” driven by food and beverage, pet-related business, and fragrance, with “strong momentum towards the end of the quarter.” At the group level, Symrise reported organic sales down 0.4%, comprised of 0.3% positive volumes and a 0.7% negative pricing contribution. Foreign exchange was described as a headwind, which management attributed largely to the stronger U.S. dollar in 2025.

By segment, the company outlined a split picture:

Taste, Nutrition & Health: organic sales +1.7%, with volume up 1% and pricing up 0.7%. Parisot cited continued strength in food and beverage, with Naturals and Savory delivering mid-single-digit growth and beverages growing low single digits. Pet Food grew low single digits, with low single-digit growth in palatability and a slight decline in pet nutrition due to price normalization despite positive volumes. Scent & Care: organic sales -3.4%, driven by negative pricing of -2.7% and volumes down -0.7%. Fragrance grew low single digits against strong comparables, supported by mid-single-digit consumer fragrance growth and low single-digit fine fragrance growth. Care and Wellness declined “low double digits,” which management primarily attributed to a double-digit decrease in UV filters against an elevated prior-year base. Aroma Molecules declined “mid-single digits” on tough comparables, while specialty fragrance ingredients performed well.

Story Continues

→ Homebuilder Earnings: D.R. Horton Sticks Out as Pulte & NVR Sales Tank

On Aroma Molecules, Parisot reiterated that the company is progressing a divestment process for the “campaign ingredient process” and is in “constructive dialogue with a strong group of bidders,” promising an update “as soon as appropriate.”

Regional trends: growth in the Americas and Asia offsets EMEA decline

Symrise reported organic sales growth of +1.9% in North America and +2.8% in Latin America, which Parisot attributed to customer demand and “strong commercial execution.” Asia Pacific grew +3.4%, which management described as broad-based across key markets.

→ Meta Platforms Earnings Preview: What to Watch in Q1 2026 Report

Those gains were offset by EMEA, where organic sales declined -4.9%. Parisot pointed to strong comparables, a soft regional macro environment, and the UV filter business as key drivers. Addressing a question on Middle East exposure, he said the region represents about 3% of Symrise sales and that recent events were “slowing down some deliveries” but “not slowing down the market demand.”

Transformation and investment: cost savings, capacity expansion, and innovation

Parisot positioned Q1 as a period of continued execution under the company’s ONE Symrise strategy and ONE SYM transformation. He said Symrise is accelerating “significant structural cost savings and efficiency gains” in order to reinvest and “unlock organic growth opportunities.”

He also highlighted operational and innovation milestones, including opening a new pet food facility in Querétaro, Mexico, which he said expands capacity and strengthens local manufacturing in a “high-growth market.” The company also took an equity stake in Bond Pet Foods, which Parisot described as providing early exposure to precision fermentation technology and positioning Symrise in sustainable protein solutions.

In Care and Wellness, Parisot said Symrise introduced three new cosmetic ingredients and early-stage concepts at the in-cosmetics Global 2026 trade show. He cited external recognition, including a Taste Bar Award for a “best tasting nutricosmetic beverage” and a Silver Fountain Award for a product called Mindera in the green and sustainable ingredient category at PCHI 2026.

On the transformation program, Parisot said that since 2023 Symrise has delivered approximately EUR 100 million in cumulative savings and expanded margin by 280 basis points, describing this as a foundation for “growth activation.” He said more detailed targets would be provided in the second half of the year and reiterated that, over time, the company aims to return to 5%–7% organic growth.

Pricing, costs, and demand: management addresses Q1 surprise and inflation

Several analysts pressed Symrise on why Q1 came in better than the company’s earlier expectation for a low-single-digit decline. Parisot said the March guidance was based on a “soft beginning of the year” and heightened uncertainty shortly after the U.S. “invaded Iran,” which led management to be cautious. He added that March was “definitely better than January and February,” and credited portfolio activation and execution.

He also acknowledged that some demand may have been pulled forward. In response to BNP Paribas analyst Nicola Tang, Parisot said Symrise had communicated early about potential price increases linked to war effects on raw materials and logistics, and “some customers, perhaps certainly, anticipated some delivery before having any price increase,” while adding that it was “very difficult to measure.”

On input costs and margin protection, Parisot said Symrise is taking actions including reformulation, price increases, and surcharges to address logistics cost inflation. “In any case, we are totally offsetting the cost we are eventually facing,” he said. In a follow-up on timing, CFO Olaf Klinger said the company is implementing price actions “this year,” describing it as “more a topic for Q2, Q3, without any delay.”

Parisot also told Morgan Stanley analyst Lisa De Neve that the company is working on two types of price actions—general price increases reflecting value provided and surcharges tied to extraordinary costs such as logistics. He added that Symrise still expects its growth mix to be “more or less two-thirds, one-third,” meaning roughly two-thirds volume and one-third price.

Outlook reaffirmed: 2026 guidance and midterm targets unchanged

Management reaffirmed full-year 2026 guidance, calling for organic sales growth of 2%–4%, an adjusted EBITDA margin of 21.5%–22.5%, and an adjusted business free cash flow margin above 14%. Parisot said the impact from the Middle East conflict has been “manageable” and does not change Symrise’s underlying growth assumptions, while freight and logistics costs remain an area of “elevated uncertainty.”

From a phasing standpoint, Parisot said year-over-year comparables are more challenging in the first part of the year and should moderate in the second half. He said Symrise expects a “sequential improvement in organic growth” over the coming quarters, supported by transformation execution, customer project momentum, and a strong innovation pipeline.

Symrise also reaffirmed its 2025–2028 targets of 5%–7% organic sales growth, an EBITDA margin between 21% and 23%, and a business free cash flow margin above 14%.

About Symrise (ETR:SY1)

Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates through two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for fish feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.

The article "Symrise Q1 Earnings Call Highlights" was originally published by MarketBeat.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Symrise AG Unsponsored ADR (SYIEY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

As such, the Zacks rating upgrade for Symrise is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Symrise imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate Revisions

Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Story Continues

Earnings Estimate Revisions for Symrise

This company is expected to earn $1.27 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Symrise. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.8%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Symrise to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Symrise AG Unsponsored ADR (SYIEY) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Symrise logo

Key Points

Symrise delivered solid 2025 results with organic sales growth of 2.8%, a 120 bps expansion in adjusted EBITDA margin, record adjusted business free cash flow of €780 million (margin 15.8%), and improved leverage (net debt €2.1 billion, 1.9x), while receiving inaugural investment‑grade ratings. The company’s ONE SYM Transformation and portfolio actions generated cumulative savings of €100 million (2024–25) and a 280 bps margin uplift; strategic moves include divestments, the Terpenes sale process, and integrating Probi into a new Care & Wellness division expected to exceed €500 million sales in 2026, alongside a proposed €400 million buyback and a 16th consecutive dividend increase to €1.25 per share. For 2026 management guided a cautious near‑term outlook — organic growth of 2.0–4.0%, adjusted EBITDA margin 21.5–22.5%, and business free cash flow margin above 14% (Q1 seen down low single digits) — while reaffirming mid‑term 2025–28 targets of 5–7% organic growth and a 21–23% EBITDA margin. Interested in Symrise AG? Here are five stocks we like better.

Symrise (ETR:SY1) used its full-year 2025 results call to outline progress under its “ONE Symrise” strategy and “ONE SYM Transformation” program, while setting a cautious near-term outlook for 2026 amid soft demand in some end markets and continued geopolitical uncertainty.

2025 performance: organic growth, margin expansion, and cash generation

CEO Jean-Yves Parisot described 2025 as a “defining year,” saying the company focused on “execution, efficiency, cash discipline, and strategic transformation” against a backdrop of “soft demand in certain end markets and continued regional volatility.”

→ IonQ in Rebound Mode: Buy the Thesis, Respect the Risk

CFO Olaf Klinger reported full-year 2025 organic sales growth of 2.8%, driven primarily by 2.2% volume growth and 0.6% pricing. Reported sales were pressured by currency translation, with foreign exchange reducing sales by EUR 194 million, which management attributed largely to U.S. dollar depreciation and other currencies. Portfolio changes also reduced reported sales by EUR 60 million, reflecting the Acofit divestment in early 2025 and the 51% divestment of the U.K. beverage trading business in March 2024.

On profitability, management highlighted the introduction of adjusted, supplemental non-IFRS measures going forward, including adjusted EBITDA, to improve comparability. Klinger said adjustments in 2025 included a EUR 150 million non-cash impairment related to Swedencare and a EUR 148 million revaluation and reclassification of the Terpenes business (described as EBITDA-neutral), as well as smaller items tied to portfolio optimization, the ONE SYM Transformation program, and antitrust investigation-related costs.

Story Continues

→ BigBear.ai Stock Is Down Big, But Smart Money Is Quietly Buying

Adjusted EBITDA margin expanded by 120 basis points in 2025, which management attributed to product mix and execution of cost savings under the transformation program. The company delivered EUR 50 million of incremental profit from efficiency initiatives in 2025, above its EUR 40 million target, after achieving EUR 50 million in 2024 as well.

Symrise also emphasized cash generation. The company reported EUR 780 million in (adjusted) business free cash flow and expanded the adjusted business free cash flow margin by 220 basis points to 15.8%, which it called a record. Management linked the improvement to higher EBITDA, lower CapEx intensity, and disciplined working capital management, including targeted inventory reductions. Net working capital was 32.5% of last-12-month sales.

Segment highlights: Taste, Nutrition & Health and Scent & Care

→ Atomic AI: Why NuScale Is the Only Option

In Taste, Nutrition & Health, Symrise reported organic growth of 2.6% and reported sales of EUR 3.0 billion. Klinger said growth was supported by food and beverage performance in beverages, Naturals, and Savory, while pet food was flat year-on-year. Adjusted EBITDA for the segment rose 5.2% to EUR 722 million, and adjusted EBITDA margin increased 160 basis points to 23.8%, which management said reflected profitable sales growth, portfolio mix, and efficiency gains.

In Scent & Care, the company reported organic growth of 3.2% on reported sales of EUR 1.901 billion, with foreign exchange described as a headwind of 3.5%. Management said fragrance delivered high single-digit organic growth across Fine Fragrances and Consumer Fragrances, while cosmetic ingredients posted a low single-digit decline due to tough comparables in UV filters; Micro Protection continued to grow. Adjusted EBITDA rose 3.5% to EUR 359 million, and the adjusted EBITDA margin improved 70 basis points to 18.9%.

Cost savings drivers, balance sheet, and shareholder returns

Management broke down the EUR 50 million in 2025 savings and efficiency gains as follows:

EUR 35 million from sourcing and procurement scale (with citrus cited as an example) EUR 10 million from productivity and capacity optimization EUR 5 million from global asset and logistics management actions (facility optimization, distribution, contract renegotiation, and logistics centers)

On the balance sheet, net debt including pension provisions and leases was EUR 2.1 billion, and net debt to adjusted EBITDA declined to 1.9x. Symrise also said it received inaugural investment-grade ratings from S&P Global and Moody’s at BBB+ and Baa1, respectively, both with stable outlooks, and updated its long-term leverage target range to 1.5x to 2.5x.

Adjusted EPS for 2025 was EUR 3.67, up 7.2% year over year, while EPS without adjusting for the Swedencare and Safene write-downs was EUR 1.78. The company proposed its 16th consecutive dividend increase to EUR 1.25 per share. Management also highlighted an inaugural EUR 400 million share buyback authorization announced in January 2026, running through October 2026.

Strategy update: transformation progress and Care & Wellness

Parisot said the ONE Symrise Strategy is built on three pillars—portfolio, growth, and efficiency—supported by sustainability, digitalization, and people as key enablers. He described the ONE SYM Transformation as the execution engine and pointed to EUR 100 million in cumulative cost savings across 2024 and 2025, alongside a 280 basis point expansion in adjusted EBITDA margin over the same period.

Portfolio actions discussed on the call included divestments (including Aqua Feed and the Champon business) and the ongoing process to divest the Terpenes business. The company also referenced the acquisition of Probi, now integrated into a newly formed Care and Wellness division (reported as a division within the health and care segment as of January 1, 2026). Parisot said Care and Wellness serves a “structurally growing market” and expects the division to exceed EUR 500 million in sales in 2026.

2026 outlook: prudent near-term view, reaffirmed midterm targets

For full-year 2026, Symrise guided for organic sales growth of 2.0% to 4.0%, an adjusted EBITDA margin of 21.5% to 22.5%, and an adjusted business free cash flow margin of above 14%. The outlook assumes Q1 organic growth down low single digits year over year, which management attributed to tougher comparables, soft pockets of demand, and additional uncertainty from conflict in the Middle East.

In Q&A, Parisot said the 2026 organic growth is expected to be “mainly driven by volumes,” while noting he could not provide a precise split between price and volume ahead of time. He characterized the Q1 view as “prudent,” while reiterating confidence in meeting full-year guidance and pointing to a “very strong pipeline” and project activity with customers.

On regional exposure, Klinger said the core Middle East region accounts for roughly 3% of group turnover, approximately EUR 140 million to EUR 150 million, while adding that impacts on logistics and transportation were difficult to assess on a fast-changing basis.

Regarding energy costs within the margin outlook, Klinger said Symrise is “relatively less exposed,” describing energy costs at around 2.5% of sales and stating that about 80% is hedged.

Looking beyond 2026, Symrise reaffirmed its 2025–2028 targets of 5% to 7% annual organic sales growth, an EBITDA margin of 21% to 23%, and a business free cash flow margin of more than 14%, citing tailwinds such as regulation, clean-label and natural demand, reformulation activity, and emerging-market expansion.

About Symrise (ETR:SY1)

Symrise AG supplies fragrances, flavorings, cosmetic active ingredients and raw materials, and functional ingredients in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates through two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; natural and sustainable ingredients for food and beverage manufacturers, baby food, and dietary supplements; product solutions and services for pet food manufacturers; sustainable ingredients and services for fish feed manufacturers to develop solutions for fish and shrimp farms; and probiotics for food supplements and functional foods.

The article "Symrise Q4 Earnings Call Highlights" was originally published by MarketBeat.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung (ca. 600 Wörter)

Symrise AG (SYIEF) veröffentlichte ihren Geschäftsbericht für 2025, der eine starke Leistung mit signifikanten positiven Indikatoren zeigte. Das Unternehmen erreichte Rekordgewinne und freien Cashflow, gestützt auf robustes organisches Wachstum und strategische Initiativen.

Wichtige Finanzkennzahlen:

• Umsatz: Der Gesamtumsatz erreichte 5,1 Milliarden, getrieben von Nutrition & Health (3 Milliarden) und Scent & Care (1,9 Milliarden).
• Organisches Umsatzwachstum: Ein gesundes 2,8% insgesamt, mit besonders starkem Wachstum in Scent & Care (3,2%) und Nutrition & Health (2,6%).
• Rentabilität: Die angepasste EBITDA-Marge stieg um 120 Basispunkte auf 23,8% (Nutrition & Health) und 18,9% (Scent & Care), was betriebliche Effizienzgewinne widerspiegelt. Es wurden insgesamt 50 Millionen in Kosteneinsparungen erzielt, was das ursprüngliche Ziel von 40 Millionen übertraf.
• Cashflow: Das Unternehmen erreichte eine Rekord-angepasste Geschäfts-Free-Cashflow-Marge von 15,8%.
• Schulden: Das Nettoverschuldungssaldo betrug 2,1 Milliarden mit einem Verschuldungsgrad gegenüber dem angepassten EBITDA von 1,9, was eine gesunde Finanzlage widerspiegelt.
• EPS: Der angepasste Gewinn pro Aktie (EPS) stieg um 7,2% auf 3,67. Es wurde eine Dividendensteigerung von 1,25 pro Aktie angekündigt, die eine 16-jährige Erfolgsreihe fortsetzte.
• Aktienkaufprogramm: Symrise kündigte eine Aktienrückkauf-Genehmigung von 400 Millionen an, beginnend im Januar 2026.

Positive Entwicklungen und strategische Maßnahmen:

Symrise zeigte Führungsstärke beim organischen Wachstum, das durch eine starke Leistung in seinen Kernmärkten für Lebensmittel und Getränke getragen wurde. Die betrieblichen Effizienzgewinne, kombiniert mit strategischen Akquisitionen (einschließlich der Integration von Probi) und Divestitionen, stärkten seine finanzielle Flexibilität. Ein neues Aktienkaufprogramm wurde gestartet, das Vertrauen in den Wert für die Aktionäre widerspiegelte.

Herausforderungen und Ausblick:

Trotz der positiven Ergebnisse steht das Unternehmen vor Herausforderungen. 2025 war durch schwachen Bedarf in bestimmten Märkten (insbesondere Nordamerika) aufgrund wirtschaftlicher Unsicherheiten, Inflation und geopolitischer Ereignisse gekennzeichnet. Währungsschwankungen (insbesondere der US-Dollar) hatten einen Umsatzrückgang von 194 Millionen Euro zur Folge. Das Unternehmen erwartet einen leichten Rückgang des organischen Umsatzes im ersten Quartal 2026 um eine Ziffer im unteren einstelligen Bereich, hauptsächlich aufgrund hoher Vergleiche und anhaltender Marktschwankungen. Der Konflikt im Nahen Osten trägt zusätzlich zur Unsicherheit bei.

Wichtige Erkenntnisse aus den Q&A:

• 2026-Guidance: Die 2026-Guidance für organisches Umsatzwachstum von 2-4% wird hauptsächlich durch Volumenwachstum angetrieben, wobei ein vorsichtiger Ansatz aufgrund aktueller Unsicherheiten gewählt wird.
• Tiernahrungsmärkte: Symrise erwartet verbesserte Dynamiken im Tierfuttermarkt im Jahr 2026, da sich die Preise normalisieren.
• Kostenmanagement: Symrise ist aufgrund einer erheblichen Absicherung (80% abgesichert) gut vor Energiepreisschwankungen geschützt.
• Wachstumsfaktoren: Es wird ein starkes Wachstum in allen strategischen Geschäftsbereichen erwartet – Lebensmittel & Getränke, Parfümerie, Tiernahrung und Körperpflege.

Warnung: GuruFocus hat 5 Warnzeichen bezüglich Symrise festgestellt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung:

Dieser Artikel vergleicht Symrise AG Unsponsored ADR (SYIEY) und Hawkins, Inc. (HWKN) für Investoren, die nach unterbewerteten Aktien suchen. Der Kern des Arguments dreht sich um die Nutzung von Zacks Investment Research’s Style Scores und Bewertungsmetriken.

Die Analyse zeigt, dass SYIEY derzeit eine stärkere "Buy"-Bewertung (Zacks Rank #2) im Vergleich zu HWKN's "Strong Sell" (Zacks Rank #5) aufweist. Dies wird vor allem durch eine optimistischere Prognose der Gewinne für SYIEY vorangetrieben.

Wertorientierte Investoren verlassen sich auf Schlüsselkennzahlen, um unterbewertete Unternehmen zu identifizieren. Beide Aktien werden anhand dieser Kennzahlen bewertet. SYIEY weist ein Forward P/E Verhältnis von 17,76 auf, was eine relativ niedrigere Bewertung im Vergleich zu HWKN's P/E von 31,81 anzeigt. Darüber hinaus ist SYIEY's PEG-Ratio von 1,19, die die erwartete EPS-Wachstumsrate berücksichtigt, günstiger als HWKN's 1,99. SYIEY's P/B-Verhältnis von 2,69 unterstützt seine unterbewertete Position zusätzlich.

Entscheidend ist, dass der Artikel schlussfolgert, dass, basierend auf diesen Kennzahlen, SYIEY die bessere Wertmöglichkeit darstellt. Die Kombination aus dem starken Zacks-Ranking und den günstigen Bewertungskennzahlen deutet auf SYIEY als die bessere Wahl für Investoren im chemischen und Spezialitätensektor hin.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung

Diese Analyse verwendet ein Zwei-Stufen-Discounted-Cash-Flow- (DCF-) Modell, um den intrinsischen Wert von Symrise (ETR:SY1), einem Unternehmen für Düfte und Aromen, zu schätzen. Das Modell deutet darauf hin, dass der Aktienkurs derzeit um 47 % unterbewertet ist, wobei der geschätzte intrinsische Wert 19 Milliarden Euro beträgt, was höher ist als der aktuelle Aktienkurs von 72,32 €.

Das Kernstück der Analyse ist die Prognose der zukünftigen Free Cash Flows (FCF) von Symrise über die nächsten zehn Jahre. Das Modell verwendet Analystenschätzungen, extrapoliert aus vergangenen FCF und passt Wachstumsraten progressiv an. Die erste Stufe geht von höheren Wachstumsraten (anfänglich 6,73 % abnehmend auf 2,80 % im 10. Jahr) aus, während die zweite Stufe niedrigere Wachstumsraten (4,09 % - 3,33 %) prognostiziert, die ein langsameres Wachstum widerspiegeln.

Wichtige Annahmen sind der Terminalwert, der mit dem Gordon-Wachstumsmodell berechnet wird, das eine konstante Wachstumsrate von 1,6 % auf der Grundlage der 5-jährigen Staatsanleihenrendite widerspiegelt. Der Terminalwert beträgt 23 Milliarden €.

Das DCF-Modell diskontiert diese zukünftigen Cashflows mit einer Kosten des Eigenkapitals von 5,6 % zurück auf den heutigen Wert, die sich auf das risikoarme Profil des Unternehmens bezieht. Der Analyst betont, dass die Genauigkeit des DCF-Modells stark von den Eingaben – den Diskontierungszinssätzen, Wachstumsraten und dem Terminalwert – abhängt. Das Modell berücksichtigt nicht die zyklische Natur der Branche oder zukünftige Kapitalanforderungen und bietet daher nur einen vereinfachten Überblick. Der Analyst hebt die Bedeutung hervor, mit den Annahmen zu spielen, um die Sensitivität der Bewertung zu ermitteln.

Die Analyse kommt zu dem Schluss, dass Symrise unterbewertet ist und eine attraktive Investitionsmöglichkeit bietet. Es wird jedoch betont, dass DCF-Modelle nur ein Werkzeug sind und Investoren andere Faktoren wie Branchentrends, den Wettbewerbsumfeld und spezifische Risiken (wie das identifizierte Warnsignal hinsichtlich zukünftiger Gewinne) berücksichtigen sollten.

Der Bericht fasst auch die wichtigsten Stärken und Schwächen (Gewinnwachstum, das die Branche übertrifft, aber niedrige Dividende im Vergleich zu anderen Unternehmen) des Unternehmens zusammen und hebt Chancen (fortgesetztes Gewinnwachstum) und Gefahren (langsameres Wachstum im Vergleich zum deutschen Markt) hervor.

Letztendlich ermutigt das Team von Simply Wall St Investoren, sich aktiv mit dem Modell auseinanderzusetzen und alternative Szenarien zu erkunden, um ein umfassendes Verständnis des wahren Wertes von Symrise zu erlangen. Sie bieten eine täglich aktualisierte DCF für alle deutschen Aktien und stellen interaktive Werkzeuge zur Erforschung von Analysten-Konsensschätzungen und zur Identifizierung hochwertiger Aktienalternativen bereit.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung:

Dieser Artikel vergleicht zwei Aktien – Symrise AG Unsponsored ADR (SYIEY) und Hawkins, Inc. (HWKN) – für Value-Investoren. Die zentrale Analyse basiert auf Zacks’ Style Scores, insbesondere der Value-Kategorie, kombiniert mit einem starken Zacks Rank. Der Zacks Rank konzentriert sich auf Kursänderungen der Gewinnprognosen, was darauf hindeutet, dass SYIEY im Moment die vielversprechendere Investition ist.

Dennoch analysieren Value-Investoren über Gewinnprognosen hinaus weitere traditionelle Finanzkennzahlen wie das Kurs-Gewinn-Verhältnis (KGV), das Kurs-Umsatz-Verhältnis (KUV), den Gewinnaufschlag, den Cashflow pro Aktie und das Kurs-Buchwert-Verhältnis (KBV).

Derzeit weist SYIEY ein Forward-KGV von 17,93, ein PEG-Verhältnis von 1,20 und ein KBV von 2,72 auf, was im Vergleich zu HWKN eine günstigere Bewertung darstellt. HWKN hingegen hat ein Forward-KGV von 31,74 und ein KBV von 5,22, was eine höhere Bewertung im Verhältnis zu seinen Vermögenswerten andeutet. Das PEG-Verhältnis für HWKN beträgt 1,98, was langsamere Wachstums-Erwartungen widerspiegelt.

Die Analyse kommt zu dem Schluss, dass SYIEY’s stärkere Kursänderungen der Gewinnprognosen und die attraktiveren Bewertungskennzahlen es zu der besseren Investitionsmöglichkeit für Value-Investoren macht. Der Artikel leitet Leser zur Herunterladung eines Berichts mit dem Titel „7 Best Stocks for the Next 30 Days“ von Zacks Investment Research.